Animal Reference Pathology

ARUP Institute for Clinical & Experimental Pathology®

Created in 1996, the ARUP Institute for Clinical and Experimental Pathology® seeks to expand the quantity, quality, and utility of laboratory medicine. Since its inception, the institute has developed approximately 620 tests that ARUP now performs in-house. Of these 620 tests, more than 400 were developed by institute scientists, while more than 200 others were improved and validated so that ARUP could perform them in-house rather than continue to refer them out. Moreover, ARUP research scientists have shared their knowledge, experience, and new developments with the scientific community by publishing more than 1,600 original peer-reviewed research publications in leading journals.

The institute’s mission is to be at the forefront of innovative research and development in clinical and experimental laboratory medicine and to continually contribute to the profession.

Research Focus

The institute's focus covers the spectrum of medical laboratory medicine:

Executive Directors

Julio Delgado, MD, MS
Co-Executive Director
(801) 583-2787

 

Sherrie L. Perkins, MD, PhD
Co-Executive Director
(801) 581-5854

Project Categories

The ARUP Institute for Clinical and Experimental Pathology® sponsors projects within four broad categories: creating new laboratory tests; improving current clinical laboratory tests; evaluating and critiquing tests, including alpha- and beta-site protocols; and conducting basic and clinical research projects. Research performed on human subjects is conducted under informed consent following the protocols approved by the University of Utah Institutional Review Board (IRB).


 

Recent Publications

Salama ME, Swierczek SI, Tashi T, Warby CA, Reading NS, Prchal JT. Calreticulin mutated prefibrotic-stage myelofibrosis and PMF represent an independent clone from coexisting CLL. Blood 2014;124(10):1691–2.

Ray JA, Kushnir MM, Palmer J, Seyed S, Rockwood AL, Meikle AW. Enhancement of specificity of aldosterone measurement in human serum and plasma using 2D-LC-MS/MS and comparison with commercial immunoassays. J Chromatogr B Analyt Technol Biomed Life Sci 2014;970C:102–07.

Sumner K, Swensen JJ, Procter M, Jama M, Wooderchak-Donahue W, Lewis T, Fong M, Hubley L, Schwarz M, Ha Y, Paul E, Brulotte B, Lyon E, Bayrak-Toydemir P, Mao R, Pont-Kingdon G, Best DH. Noncontinuously binding loop-out primers for avoiding problematic DNA sequences in PCR and sanger sequencing. J Mol Diagn 2014;16(5):477–80.

Suh-Lailam B, Carlisle HJ, Ohman T, McMillin GA. Reference interval determination of anabasine: a biomarker of active tobacco use. J Anal Toxicol 2014;38(7):416–20.

Zabriskie MS, Eide CA, Tantravahi SK, Vellore NA, Estrada J, Nicolini FE, Khoury HJ, Larson RA, Konopleva M, Cortes JE, Kantarjian H, Jabbour EJ, Kornblau SM, Lipton JH, Rea D, Stenke L, Barbany G, Lange T, Hernández-Boluda JC, Ossenkoppele GJ, Press RD, Chuah C, Goldberg SL, Wetzler M, Mahon FX, Etienne G, Baccarani M, Soverini S, Rosti G, Rousselot P, Friedman R, Deininger M, Reynolds KR, Heaton WL, Eiring AM, Pomicter AD, Khorashad JS, Kelley TW, et al. BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer Cell 2014;26(3):428–42.